Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Choroidal Neovascular Membrane Recurrence Rate in Wet AMD Patients Stable on Three Month Ranibizumab Dosing

NCT01453920 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT01453920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01453920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Choroidal Neovascular Membrane Recurrence Rate in Wet AMD Patients Stable on Three Month Ranibizumab Dosing
Lead sponsor
University Health Network, Toronto
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2011
Completion date
July 31, 2012
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration